Ocugen Advances Gene Therapies for Inherited Retinal Diseases, Eyes 2026 BLA Filings
For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of progress in gene therapy development offers significant hope. Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, recently provided a business update alongside its second-quarter 2025 financial results. This update highlights continued advancements in their clinical programs for retinitis pigmentosa (RP) and Stargardt disease, two IRDs that profoundly impact vision and quality of life. The company's commitment to developing gene-agnostic therapies is particularly relevant, as it aims to address a broader patient population regardless of their specific genetic mutation.
Ocugen reported on key developments in its gene therapy pipeline. The company is actively dosing patients in the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa. This trial remains on track for a Biologics License Application (BLA) filing in 2026. Additionally, Ocugen has initiated dosing in the OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trial, which targets Stargardt disease. These are significant steps forward in bringing potential new treatments closer to the IRD community.
Further demonstrating its commitment, Ocugen announced that it signed a binding term sheet for exclusive Korean rights to OCU400. This agreement includes upfront fees and near-term development milestone payments totaling up to $11 million. The company also received Rare Pediatric Disease Designation (RPDD) from the FDA for OCU410ST for the treatment of Stargardt disease. This designation underscores the urgent need for therapeutic options for Stargardt patients, many of whom are children. If the Priority Review Voucher (PRV) program is reauthorized, this designation could potentially lead to the award of a PRV, which incentivizes drug development for serious rare pediatric diseases.
For patients and families, these updates signify continued momentum in the quest for effective treatments for inherited retinal diseases. The gene-agnostic approach of therapies like OCU400 and OCU410ST is particularly promising because it means these treatments could potentially benefit a wider range of individuals with RP and Stargardt disease, irrespective of the specific genetic mutation causing their condition. This could simplify diagnosis and broaden access to treatment once approved. The active progression of these clinical trials, along with the strategic partnerships and regulatory designations, suggests that Ocugen is advancing its programs with the goal of making these therapies available to those who need them.
Ocugen stated its aim to support three successful BLA filings over the next three years. The company's cash, cash equivalents, and restricted cash totaled $27.3 million as of June 30, 2025, which is expected to provide a cash runway into the first quarter of 2026. These financial and operational updates reflect ongoing efforts to bring modifier gene therapies to patients with inherited retinal diseases.